Understanding how tumors suppress the immune system in aggressive breast cancer.
Dissecting Molecular Mechanisms of Tumor-Induced Myeloid-Mediated Immune Suppression in Triple-Negative Breast Cancer
This study is looking at how triple-negative breast cancer affects the immune system, especially how the cancer cells interact with certain immune cells, to find new ways to improve treatments for patients with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Toledo Health Sci Campus NIH-funded |
| Lab location | 1 site (Toledo, United States) |
| Project ID | NIH-10976123 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which triple-negative breast cancer (TNBC) affects the immune system, particularly focusing on how tumor cells influence myeloid-derived suppressor cells and other immune cells. The study utilizes advanced techniques such as mass cytometry to analyze immune cell interactions and the role of specific genes in tumor progression. By examining mouse models, the research aims to uncover new therapeutic targets that could enhance the effectiveness of immunotherapy in TNBC patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who may benefit from novel immunotherapy approaches.
Not a fit: Patients with non-triple-negative breast cancer subtypes or those who are not eligible for immunotherapy may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy strategies for patients with triple-negative breast cancer, potentially increasing survival rates.
How similar studies have performed: Previous studies have shown promise in using immunotherapy for breast cancer, but this specific approach focusing on the TAZ gene in TNBC is relatively novel.
Where this research is happening
Toledo, United States
- University of Toledo Health Sci Campus — Toledo, United States (Active)
Researchers
- Principal investigator: Zhang, Jianmin — University of Toledo Health Sci Campus
- Study coordinator: Zhang, Jianmin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.